In this episode, I am thrilled to welcome Dan Lynch, an Executive Venture Partner at Google Ventures and a seasoned leader in the biotechnology sector.
Since joining GV in 2021, Dan has partnered with life sciences CEOs and executives, providing invaluable guidance as a trusted advisor and coach. His commitment to fostering long-term relationships underscores his belief that collaboration is essential in an industry filled with talented people.
Dan brings a wealth of experience, having worked with numerous biopharmaceutical companies, including notable names like ImClone, where he served as CEO and CFO. Under his leadership, ImClone achieved a remarkable turnaround and secured FDA approval for the groundbreaking cancer treatment ERBITUX®.
With a focus on placing patients at the center of every initiative, Dan emphasizes the importance of impact and community in the biotech landscape. He currently serves on the boards of several innovative companies and has a rich history of successful investments and partnerships.
Join us as we dive into Dan’s insights into the world of biotechnology, the importance of collaboration, his experience turning around ImClone and what it truly means to prioritize patient impact in this ever-evolving field.